1、Arzneimittelforschung. 1985;35(7A):1203-8. Ohashi S, Iwatani M, Hyakuna Y, Morioka Y. Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion. 2、Arzneimittelforschung. 1985;35(7A):1149-54. K Kawamura, K Watanabe, Y Kimura. Effect of cilostazol, a new antithrombotic drug, on cerebral circulation 3、Gel formation of cefpodoxime proxetil 4、Gas chromatographic analysis of fosfomycin in plasma for pharmacokinetic analysis. GK Webster, RG Bell - Journal of AOAC International, 1999 - europepmc.org 5、Rydell N, Butler J, Balazs EA. Hyaluronic acid in synovial fluid.Ⅵ. Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of the arthritis in track horses. Acta Vet Scand, 1970,11:139~146 6、Peyron JG, Balazs EA. Preliminary clinical assessment of Na-hyaluronate injection into human arthritic joints. Pathol Biol, 1974, 22:731~736 7、Weiss C, Balazs EA, St Onge R, et al. Clinical studies of the intra-articular injection of Healon in the treatment of osteoarthritis of human knee. Semin Arhtritis Rheum, 1980, 11(Suppl 1):143~144 8、Punzi L, Schiavon F, Ramonda R, et al. Intra-articular hyaluronic acid in the treatment of inflammatory and non-inflammatory knee diffusions. Curr Ther Res, 1988, 43:643~647 9、Nolan JP, reducing Catheter Related Bacteraemia in Haemodialysis. Vascular Access Soc. 5th Int. Congress of Vascular Access Soc, Nice, 2007 10、Arzneimittelforschung. 1984;34(9):948-52. Iron derivatives of modified milk protein.   [更多]

MONOGRAPHS: Levofloxacin《USP43-NF38》的藥典標(biāo)準(zhǔn)一份 USP MONOGRAPHS: Levofloxacin Tablets《USP43-NF38》的藥典標(biāo)準(zhǔn)一份 Levofloxacin Tablets《USP–NF 2021(Issue 2)》的藥典標(biāo)準(zhǔn)一份 Levofloxacin《USP–NF 2021(Issue 2)》的藥典標(biāo)準(zhǔn)一份 左氧氟沙星、片藥品注冊標(biāo)準(zhǔn) Levofloxacin Fine Granules《JP17(英)》的藥典標(biāo)準(zhǔn)一份   [更多]

標(biāo)題：請人查關(guān)于Faropenem Sodium Hydrate《JP17(英)》及Faropenem Sodium Tablets《JP17(英)》的藥典標(biāo)準(zhǔn) 需求名稱：Faropenem Sodium Hydrate《JP17(英)》及Faropenem Sodium Tablets《JP17(英)》的藥典標(biāo)準(zhǔn) 價格預(yù)算：50元 需求時間：請在2020年11月28號之前提交 交稿方式：請將文獻(xiàn)直接打包在藥智網(wǎng)交稿就可以了   [更多]

1、懸賞的藥品注冊信息為2016年1月1日之后不批準(zhǔn)、退審的藥品注冊信息和補(bǔ)充藥品注冊信息 2、必須提供完整注冊信息,以附件形式提交 （以單個批件形式提交）3、核實(shí)后如果正確,每個藥品注冊信息獎勵100元 4、投稿時請隱藏提交 5、請勿在百度上直接搜索 6、需是未收集的數(shù)據(jù)   [更多]

1、Przemysl Chemiczny, 85(5), 349-350; 2006 2、Polymorphism of sodium valproate 【作 者】Mifsud, H.;Miguel, L.;Lavastre, V.;Maire, G. 【刊 名】Calorim. Anal. Therm. 【出版日期】1993 【卷 號】Vol.24 【頁 碼】309-312 3、Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC 4、[Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group] 5、Ital J Gastroenterol. 1995 Sep;27(7):376-7. TUDCA and UDCA are incorporated into hepatocyte membranes: different sites, but similar effects. Leuschner U1, Guldutuna S, Bhatti S, Elze A, Imhof M, You T, Zimmer G. Author information 6、AJHYA2 American Journal of Hygiene. (Baltimore, MD) V.1-80, 1921-64. For publisher information, see AJEPAS. Volume(issue)/page/year: 76,209,1962   [更多]

Cotton, Absorbent《USP42-NF37》的藥典標(biāo)準(zhǔn)一份   [更多]

USP43 最新電子版   [更多]

求一套滿足GVP的藥物警戒體系文件，謝謝！   [更多]

求 制藥企業(yè)用藥物警戒體系全套文件 詳細(xì)要求： 需求名稱：藥物警戒體系全套文件。 具體要求：按《藥物警戒質(zhì)量管理規(guī)范》2021年版要求編制。 要求時間：請在2021年10月20日之前。 交稿方式：直接點(diǎn)擊交稿在線交稿   [更多]

Levocarnitine  CAS : 541-15-1《EP10.5》的藥典標(biāo)準(zhǔn) 全文   [更多]